CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 265 · Search date 2026-07-11 · Methodology v0.6

Calcium alpha-ketoglutarate,
does it really help with Reduction in biological age and lifespan extension?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Combination-product observational signals exist, but human efficacy results for Ca-AKG alone are absent, so the judgment is deferred
What the
research shows
No human efficacy result is available to judge Ca-AKG alone for reducing biological age or extending lifespan. The 42-person report of an approximately eight-year reduction was an uncontrolled retrospective analysis of Rejuvant, which combines Ca-AKG with vitamins, while the pure Ca-AKG ABLE RCT has published only a protocol and recruitment report. General AKG use was not significant in the 4,260-person cross-sectional dataset, so the judgment is deferred.
What the
ads claim
Marketing links lower DNA-methylation-clock values to reversal of actual age and lifespan extension. Current human data concern a calculated biological-age surrogate, not disease incidence, functional independence, mortality, or lifespan.
*

Useful facts when choosing a product

  • The observational studies evaluated a delayed-release combination containing Ca-AKG and vitamins.
  • The retrospective before-and-after analysis included 42 people with about seven months of average use.
  • The planned ABLE RCT dose is delayed-release Ca-AKG 1 g/day.
  • No result directly measuring human lifespan extension was found.
Gap Measurement · Verdict 265 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Demidenko 2021 compared TruAge DNA-methylation age before and after four to ten months of Rejuvant, a combination of Ca-AKG and vitamins, in 42 people and reported an average reduction of about eight years, but the analysis was uncontrolled and retrospective. The Sandalova 2023 and Lim 2025 ABLE publications concern the protocol and recruitment of a pure Ca-AKG RCT, not efficacy results. In the Pabis 2026 cross-sectional cohort of 4,260 people, an association was observed for a delayed-release Ca-AKG combination, whereas general AKG use was not significant.

02

Why this is classified as ?

Positive observational evidence concerns a Ca-AKG-plus-vitamin combination, the pure Ca-AKG ABLE RCT has no efficacy result, and the association for general AKG was not significant; human efficacy for Ca-AKG alone is therefore ungraded.

Counterpoint. The association with DNA-methylation age remains a hypothesis for randomized follow-up. This judgment does not convert animal lifespan data into human lifespan evidence.

Rejudgment record. Reassessment (cross-check reflected) — Positive evidence is an uncontrolled retrospective analysis of a Ca-AKG-plus-vitamin combination; pure Ca-AKG has no ABLE efficacy result, and general AKG use was not significant cross-sectionally

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Demidenko O et al. 2021Retrospective single-arm before-and-after analysis42Links to Ponce de Leon Health and TruMeTruAge DNA-methylation ageCalculated age fell by about eight years after roughly seven months, but there was no control group and the product was a combination.Key
Sandalova E et al. 2023; Lim ZM et al. 2025Double-blind RCT protocol and recruitment-feasibility report120Lien Foundation; investigator advisory link to product companyDNA-methylation age, metabolic markers, and functionOnly the design and recruitment results have been published; efficacy results were not available.Supportive
Pabis K et al. 2026Cross-sectional observational cohort4,260Academic study with disclosed product-related interestsNine-CpG age residualDelayed-release Ca-AKG combination use was associated with a 1.8-year lower age residual, but general AKG use was not significant and healthy-user bias remains possible.Supportive
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Demidenko O, Barardo D, Budovskii V, et al. 2021. Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY). 13(22):24485-24499. PMID: 34847066. DOI: 10.18632/aging.203736.
checked
Sandalova E, Goh J, Lim ZX, Lim ZM, Barardo D, Dorajoo R, Kennedy BK, Maier AB. 2023. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)-intervention study protocol. GeroScience. 45(5):2897-2907. PMID: 37217632. DOI: 10.1007/s11357-023-00813-6.
checked
Pabis K, Wang W, Selvarajoo K, et al. 2026. Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals. Aging Cell. 25(6):e70517. PMID: 42166733. DOI: 10.1111/acel.70517.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Calcium alpha-ketoglutarate (Ca-AKG) x Reduction in biological age and lifespan extension Evidence Grade ? card
[Chamgap] Calcium alpha-ketoglutarate (Ca-AKG) x Reduction in biological age and lifespan extension — Evidence Grade ?. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/antioxidant-aging/calcium-alpha-ketoglutarate-biological-age-longevity/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.